Drug
Zuberitamab
Zuberitamab is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting2
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (75.0%)
N/A1 (25.0%)
Trials by Status
active_not_recruiting125%
recruiting125%
not_yet_recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_2
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
NCT07480863
not_yet_recruitingphase_2
Zuberitamab for EBV Infection Post-Allo-HSCT
NCT07261215
recruitingnot_applicable
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
NCT07257510
not_yet_recruitingphase_2
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
NCT06757894
Clinical Trials (4)
Showing 4 of 4 trials
NCT07480863Phase 2
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
NCT07261215Phase 2
Zuberitamab for EBV Infection Post-Allo-HSCT
NCT07257510Not Applicable
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
NCT06757894Phase 2
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4